Skip to main content
ResearchTreatments

Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR-Mutant NSCLC

*September 2024*

The investigational HER​​3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd) elicited a statistically significant improvement in progression-free survival (PFS) vs platinum-based chemotherapy in patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) who were previously exposed to an EGFR TKI, meeting the primary end point of the phase 3 HERTHENA-Lung02 trial (NCT05338970).1

Overall survival data remain immature at the time of this analysis and will be further assessed as a secondary end point of the trial. Additionally, no new safety signals were reported with patritumab deruxtecan, and the agent exhibited a toxicity profile consistent with that observed in prior studies in NSCLC. Notably, interstitial lung disease (ILD) events were primarily grade 1/2, with 2 grade 5 ILD events reported.

These results will be presented at an upcoming medical meeting and submitted to global regulatory bodies.

“These results from HERTHENA-Lung02 demonstrate the potential of patritumab deruxtecan to become an important treatment option for certain patients with EGFR-mutated NSCLC with prior TKI treatment,” Ken Takeshita, MD, global head of research and development at Daiichi Sankyo, stated in a news release. “We plan to share these findings with regulatory authorities to discuss next steps.” Read more.

Share